Natco Pharma USA Successfully Integrates DASH Pharmaceuticals, Strengthening Strategic Presence in the United States
Wednesday, January 03, 2024
Natco Pharma Limited, an Indian pharmaceutical company primarily focused on research and development (R&D), has officially declared the transition of DASH Pharmaceuticals to Natco Pharma USA, its U.S. subsidiary. Starting from January 2, all products previously marketed by DASH will now fall under the Natco Pharma USA label, maintaining the existing National Drug Code (NDC) Numbers.
Subba Rao Mente, Chief Executive Officer of Natco Pharma USA, emphasized the significance of this move, stating that it provides the company with a strategic presence in the United States and strengthens its direct connection with valued customers in this critical market. Julie Trendowicz and Nick DiMaio, former executives of DASH, will retain their roles as Executive Vice President and President, respectively, under Natco Pharma USA.
Natco Pharma has been actively involved in the U.S. market since 2007, forming co-development and licensing partnerships with leading U.S. generic pharmaceutical companies. These collaborations have resulted in the successful development and launch of various first-to-market generics and complex formulations. Notable products include Lenalidomide Capsules, Glatiramer Acetate Pre-Filled Syringes, Liposomal Doxorubicin Vials, Oseltamivir Phosphate Capsules, Lanthanum Carbonate Chewable Tablets, Everolimus Tablets, and Lapatinib Tablets.
The company's accomplishments have established Natco Pharma as a reputable entity in the U.S. generic pharmaceutical industry. With the establishment of Natco Pharma USA, the company aims to further enhance the accessibility and affordability of its generic products, marking a significant step towards a broader expansion in the U.S. market.
Source: businesswire.com
